Investor Presentaiton

ΤΗΣ Biocon Biologics- Making Global Impact with Biosimilars MANIFE Biocon Biologics Portfolio Development Stage Therapeutic Areas 'Pure Play' Biosimilars Company Molecule Pegfilgrastim US Trastuzumab Oncology Bevacizumab Pertuzumab Fully integrated - lab to market Adalimumab* Etanercept* Immunology Undisclosed Undisclosed Global Footprint (120+ countries) Strong collaborations (Viatris & Sandoz) Diabetes Ophthalmology Bone Health Glargine** 100U Glargine 300U Aspart RHI^^ Undisclosed Undisclosed Undisclosed Europe Most of World^^ $ Originator WW 2019 Net Sales ($ Bn) Biocon -20 Early Dev./ Preclinical -37 Clinical Filed ~13 Approved / Commercialised -8 -5 Commercial infrastructure in India (BFI) 28- Portfolio Products 7 Commercial Products *Partner Viatris has in-licensed product (Biocon benefits from economic interest); **Japan is outside of Viatris partnership; ^RHI completed Ph1 and considering potential Ph-3 waiver to be confirmed with FDA advice, shown as Planned submission. Note: Viatris is responsible for commercialisation of all the disclosed products mentioned above except RHI in US and EU. "Chart represents the status of the country where the product is in most advanced stage. Every country has a different status 30 2 R&D sites (2 Bengaluru, 1 Malaysia) Manufacturing sites 25+1 CGMP approvals (incl. FDA & EMA) Touching a billion lives through affordable innovation 10

View entire presentation